Show simple item record

dc.contributor.advisorDobrowsky, Rick T
dc.contributor.authorPan, Pan
dc.date.accessioned2016-10-11T16:11:34Z
dc.date.available2016-10-11T16:11:34Z
dc.date.issued2014-05-31
dc.date.submitted2014
dc.identifier.otherhttp://dissertations.umi.com/ku:13353
dc.identifier.urihttp://hdl.handle.net/1808/21637
dc.description.abstractAberrant neuron-glia interactions can contribute to a variety of neurodegenerative diseases. We have previously demonstrated that enhanced activation of Erb B2, which is a member of the epidermal growth factor receptor (EGFR) family, can contribute to the development of diabetic peripheral neuropathy (DPN). In peripheral nerves, Erb B receptors are activated by various members of the neuregulin-1 (NRG1) family including NRG1 Type I, NRG1 Type II and NRG1 Type III to regulate Schwann cell growth, migration, differentiation and dedifferentiation. Alternatively, Erb B2 activity can be negatively regulated by association with the Erb B2-interacting protein, erbin. Since the effect of diabetes on the expression of NRG1 isoforms and erbin in peripheral nerve are unknown, the current study determined whether changes in NRG1 isoforms and erbin may be associated with altered Erb B2 signaling in DPN. Swiss Webster mice were rendered diabetic with streptozotocin (STZ) and after 12 weeks of diabetes, treated with erlotinib, an inhibitor of Erb B2 activation. Inhibition of Erb B2 signaling partially reversed several pathophysiologic aspects of DPN including a pronounced sensory hypoalgesia, nerve conduction velocity deficits and the decrease in epidermal nerve fiber innervation. We also observed a decrease of NRG1 Type III but an increase of NRG1 Type I level in diabetic sural nerves at early stage of diabetes. With disease progression, we detected reduced erbin expression and enhanced MAPK pathway activity in diabetic mice. Pharmacologic inhibition of Erb B2 suppressed MAPK activity in diabetic sural nerves. These results support that hyperglycemia may impair NRG1-Erb B2 signaling by disrupting the balance between NRG1 isoforms, decreasing the expression of erbin and correspondingly activating the MAPK pathway. Together, imbalanced NRG1 isoforms and downregulated erbin may contribute to the dysregulation of Erb B2 signaling in the development of DPN
dc.format.extent155 pages
dc.language.isoen
dc.publisherUniversity of Kansas
dc.rightsCopyright held by the author.
dc.subjectPharmacology
dc.subjectErlotinib
dc.subjectIntra epidermal nerve fibers
dc.subjectNerve conduction velocity
dc.subjectSensory hypoalgesia
dc.titleDifferential expression of neuregulin-1 isoforms and downregulation of erbin are associated with Erb B2 receptor activation in diabetic peripheral neuropathy
dc.typeDissertation
dc.contributor.cmtememberStaudinger, Jeff L
dc.contributor.cmtememberMoise, Alexander R
dc.contributor.cmtememberShi, Honglian
dc.contributor.cmtememberAckley, Brian D
dc.thesis.degreeDisciplinePharmacology & Toxicology
dc.thesis.degreeLevelPh.D.
dc.identifier.orcidhttps://orcid.org/0000-0002-9573-9443
dc.provenance04/04/2017: The ETD release form is attached to this record as a license file.
dc.rights.accessrightsopenAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record